BACKGROUND: Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count. OBJECTIVE: To estimate the independent impact of HAART on reducing ODs and mortality in Côte d'Ivoire. METHODS: Within two longitudinal studies of HIV-infected adults (1996-2003), we identified time on 'cotrimoxazole alone' and 'HAART plus cotrimoxazole' WHO stage 3-4 defining events and severe malaria were divided into those preventable and not preventable with cotrimoxazole. Incidence of ODs by CD4 count stratum was estimated using incidence density analysis. CD4+ T-cell count at time of OD was estimated using linear interpolation. Using Poisson regression, we estimated the effect of HAART on OD incidence and mortality by CD4 count stratum. RESULTS: Totals of 446 and 135 adults were followed during 6,216 and 3,412 person-months in the cotrimoxazole alone and HAART plus cotrimoxazole periods, respectively. There was a CD4+ T-cell-independent risk reduction for ODs and mortality during the HAART plus cotrimoxazole period compared with cotrimoxazole alone, which varied by time on HAART, CD4 count stratum and OD type. It was mainly seen after 6 months on HAART and for ODs not preventable by cotrimoxazole. The HAART effect differed significantly by CD4 count stratum (P=0.02), but was significant in all strata after 6 months on HAART. CONCLUSIONS: In these sub-Saharan African adults, HAART initiation reduced ODs and mortality beyond that which was expected through the HAART-induced CD4+ T-cell increase. Further studies should examine practical implications of this independent 'HAART effect' on clinical outcomes in patients on HAART.
BACKGROUND: Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infectedpatients beyond that which is expected from changes in CD4+ T-cell count. OBJECTIVE: To estimate the independent impact of HAART on reducing ODs and mortality in Côte d'Ivoire. METHODS: Within two longitudinal studies of HIV-infected adults (1996-2003), we identified time on 'cotrimoxazole alone' and 'HAART plus cotrimoxazole' WHO stage 3-4 defining events and severe malaria were divided into those preventable and not preventable with cotrimoxazole. Incidence of ODs by CD4 count stratum was estimated using incidence density analysis. CD4+ T-cell count at time of OD was estimated using linear interpolation. Using Poisson regression, we estimated the effect of HAART on OD incidence and mortality by CD4 count stratum. RESULTS: Totals of 446 and 135 adults were followed during 6,216 and 3,412 person-months in the cotrimoxazole alone and HAART plus cotrimoxazole periods, respectively. There was a CD4+ T-cell-independent risk reduction for ODs and mortality during the HAART plus cotrimoxazole period compared with cotrimoxazole alone, which varied by time on HAART, CD4 count stratum and OD type. It was mainly seen after 6 months on HAART and for ODs not preventable by cotrimoxazole. The HAART effect differed significantly by CD4 count stratum (P=0.02), but was significant in all strata after 6 months on HAART. CONCLUSIONS: In these sub-Saharan African adults, HAART initiation reduced ODs and mortality beyond that which was expected through the HAART-induced CD4+ T-cell increase. Further studies should examine practical implications of this independent 'HAART effect' on clinical outcomes in patients on HAART.
Authors: Rony Zachariah; Margaret Fitzgerald; Moses Massaquoi; Olesu Pasulani; Line Arnould; Simon Makombe; Anthony D Harries Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: E Girardi; F Palmieri; A Cingolani; A Ammassari; N Petrosillo; L Gillini; D Zinzi; A De Luca; A Antinori; G Ippolito Journal: J Acquir Immune Defic Syndr Date: 2001-04-01 Impact factor: 3.731
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: V Miller; C A Sabin; A N Phillips; C Rottmann; H Rabenau; E Weidmann; V Rickerts; S Findhammer; E B Helm; S Staszewski Journal: AIDS Date: 2000-09-29 Impact factor: 4.177
Authors: Elizabeth L Corbett; Gavin J Churchyard; Salome Charalambos; Badara Samb; Vicky Moloi; Tim C Clayton; Alison D Grant; Jill Murray; Richard J Hayes; Kevin M De Cock Journal: Clin Infect Dis Date: 2002-04-05 Impact factor: 9.079
Authors: J S Currier; P Williams; J Feinberg; S Becker; S Owens; C Fichtenbaum; C Benson Journal: Clin Infect Dis Date: 2001-04-30 Impact factor: 9.079
Authors: A Gregory DiRienzo; Charles van Der Horst; Dianne M Finkelstein; Peter Frame; Samuel A Bozzette; Karen T Tashima Journal: AIDS Res Hum Retroviruses Date: 2002-01-20 Impact factor: 2.205
Authors: Sarah B Lorenzana; Michael D Hughes; Beatriz Grinsztejn; Ann C Collier; Paula Mendes Luz; Kenneth A Freedberg; Robin Wood; Julie H Levison; Peter N Mugyenyi; Robert Salata; Carole L Wallis; Milton C Weinstein; Robert T Schooley; Rochelle P Walensky Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: April D Kimmel; Macarthur Charles; Marie-Marcelle Deschamps; Patrice Severe; Alison M Edwards; Warren D Johnson; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Rochelle P Walensky; Lindsey L Wolf; Robin Wood; Mariam O Fofana; Kenneth A Freedberg; Neil A Martinson; A David Paltiel; Xavier Anglaret; Milton C Weinstein; Elena Losina Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Rochelle P Walensky; Robin Wood; Milton C Weinstein; Neil A Martinson; Elena Losina; Mariam O Fofana; Sue J Goldie; Nomita Divi; Yazdan Yazdanpanah; Bingxia Wang; A David Paltiel; Kenneth A Freedberg Journal: J Infect Dis Date: 2008-05-01 Impact factor: 5.226
Authors: Eric N Ouattara; Marion Robine; Serge P Eholié; Rachel L MacLean; Raoul Moh; Elena Losina; Delphine Gabillard; A David Paltiel; Christine Danel; Rochelle P Walensky; Xavier Anglaret; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2016-03-01 Impact factor: 9.079
Authors: Jordan A Francke; Martina Penazzato; Taige Hou; Elaine J Abrams; Rachel L MacLean; Landon Myer; Rochelle P Walensky; Valériane Leroy; Milton C Weinstein; Robert A Parker; Kenneth A Freedberg; Andrea Ciaranello Journal: J Infect Dis Date: 2016-08-17 Impact factor: 5.226
Authors: Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg Journal: PLoS Med Date: 2009-10-27 Impact factor: 11.069